Jianing Liu

Jianing Liu

Auto-generated profile, based on publicly available information

Jianing Liu

Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZZZaikuan Zhang
Zaikuan Zhang
YXYajun Xie
Yajun Xie
QYQiying Yi
Qiying Yi
JLJianing Liu
Jianing Liu
LYLin Yang
Lin Yang
QZQin Zhou
Qin Zhou
Tight junctions are crucial for maintaining intestinal barrier homeostasis, but how organisms modulate these junctions remain unclear. Here, we show a role for PEAK1 at cell-cell contact sites, where it interacts with ZO-1 via a conserved region spanning amino acids 714-731. This interaction masks the LC3-interacting region on ZO-1, preventing autophagy-mediated ZO-1 degradation and preserving the integrity of tight junctions in intestinal epithelial cells. Src-mediated phosphorylation of PEAK1 at Y724 promotes the binding between PEAK1 and ZO-1 to stabilize ZO-1 in intestinal epithelial cells. Additionally, PEAK1 binds to CSK to positively regulate Src activity. Loss of PEAK1 in intestinal epithelial cells leads to decreased Src activity and lower ZO-1 protein levels, resulting in disrupted tight junctions, both in vitro and in vivo. In mice, Peak1 deficiency increases intestinal epithelium permeability and exacerbates inflammation in experimentally induced colitis models. Our findings reveal PEAK1’s critical role in maintaining tight junction integrity and resistance to intestinal inflammation, extending its known function from promoting tumor cell proliferation and migration to essential physiological processes. These insights refine our understanding of the mechanisms regulating tight junctions and offer potential therapeutic targets for enhancing epithelial barrier function and treating related diseases.

19 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
YXYajun Xie
Yajun Xie
XLXiaoyan Lv
Xiaoyan Lv
DNDongsheng Ni
Dongsheng Ni
JLJianing Liu
Jianing Liu
YHYanxia Hu
Yanxia Hu
QZQin Zhou
Qin Zhou
Decreased expression of 4-hydroxyphenylpyruvic acid dioxygenase (HPD), a key enzyme for tyrosine metabolism, is a cause of human tyrosinemia. However, the regulation of HPD expression remains largely unknown. Here, we demonstrate that molecular chaperone TTC36, which is highly expressed in liver, is associated with HPD and reduces the binding of protein kinase STK33 to HPD, thereby inhibiting STK33-mediated HPD T382 phosphorylation. The reduction of HPD T382 phosphorylation results in impaired recruitment of FHA domain-containing PELI1 and PELI1-mediated HPD polyubiquitylation and degradation. Conversely, deficiency or depletion of TTC36 results in enhanced STK33-mediated HPD T382 phosphorylation and binding of PELI1 to HPD and subsequent PELI1-mediated HPD downregulation. Ttc36−/− mice have reduced HPD expression in the liver and exhibit tyrosinemia, damage to hippocampal neurons, and deficits of learning and memory. These findings reveal a previously unknown regulation of HPD expression and highlight the physiological significance of TTC36-STK33-PELI1-regulated HPD expression in tyrosinemia and tyrosinemia-associated neurological disorders.

9 July 2023 in Journal of Cleaner Production
Verified
Journal Article
Closed access
QGQiusheng Gao
Qiusheng Gao
Liang DuanLiang Duan
Liang Duan
JLJianing Liu
Jianing Liu
HZHengliang Zhang
Hengliang Zhang
YZYang Zhao
Yang Zhao

1 January 2020 in Gene
Verified
Journal Article
Closed access
QYQiying Yi
Qiying Yi
YLYang Liu
Yang Liu
MCMin Cao
Min Cao
JLJianing Liu
Jianing Liu
QXQin Xiang
Qin Xiang
YXYajun Xie
Yajun Xie